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ABSTRACT: Three-dimensionally organized lipid cubic self-assemblies and
derived oil-in-water emulsions called “cubosomes” are attractive for various
biotechnological applications due to their ability to be loaded with functional
molecules and their associated sustained release properties. Here, we employed
both of these lipid-based systems for the delivery of a model drug, aspirin, under
comparable conditions. Studies were performed by varying drug-to-lipid ratio
and the type of release medium, water and phosphate buﬀer saline (PBS).
Release rates were determined using UV−vis spectroscopy, and small-angle X-
ray scattering was used to conﬁrm the type of self-assembled nanostructures
formed in these lipid systems. The release from the bulk lipid cubic phase was
sustained as compared to that of dispersed cubosomes, and the release in PBS
was more eﬃcient than in water. The tortuosity of the architecture, length of the
diﬀusion pathway, type of nanostructure, and physicochemical interaction with
the release media evidently contribute to these observations. This work is
particularly important as it is the ﬁrst report where both of these nanostructured lipid systems have been studied together under
similar conditions. This work provides important insights into understanding and therefore controlling the release behavior of
lipid-based drug nanocarriers.
■ INTRODUCTION
Lipids, generally composed of hydrophilic and hydrophobic
molecular components (Figure 1a), tend to self-assemble in the
presence of aqueous media. Self-assemblies can be as simple as
spherical micelles and planar bilayers, or they can be quite
elegant like hexagonal and cubic phases.1,2 On the basis of their
spatial organization, lipid cubic phases are divided into two
types, bicontinuous and micellar.3 Most common bicontinuous
cubic phases (Figure 1b), deﬁned by crystallographic space
groups Ia3d (no. 230), Pn3m (no. 224), and Im3m (no. 229),
are formed by draping a continuous lipid bilayer on gyroid (G),
diamond (D), and primitive (P) type periodic minimal surfaces,
respectively.3,4 The term bicontinuous can be interpreted in
two possible ways: (1) the continuity of two networks, the ﬁrst
made of a continuous bilayer and the second made of
continuous waterways, and (2) the presence of two continuous
aqueous channels separated by a single lipid bilayer.5 Micellar
cubic phases, on the other hand, are formed by an arrangement
of discrete micelles in a cubic lattice.3 A typical example of a
micellar cubic phase is the Fd3m phase.6
Bicontinuous cubic phases are equipped with a range of
structural features responsible for their applicability, for
instance, (a) enormous surface area (400 m2/g),7 (b) large
surface-to-volume ratio, (c) physicochemical ability to load
hydrophilic molecules in the aqueous region, hydrophobic
molecules in the lipid chain region, and amphiphilic molecules
in bilayers,8 (d) continuous trajectories for uninterrupted
diﬀusion of loaded molecules,5 (e) viscoelastic nature to
provide stability and structural integrity for loaded molecules,9
(f) highly organized porous network for nanoscale templat-
ing,10 and (g) resemblance to biomembrane structures.11
Further aspects include thermodynamic equilibrium12 and
robustness under given conditions as well as a high level of
tunability. However, the preparation and handling of cubic
phases are not simple protocols due to their inherently high
viscosity (complex viscosity in the range of 104−105 Pa·s)13
(Figure 1c). Two possible ways to overcome these hurdles are
to utilize mechanical tools to handle cubic phases14−16 or to
disperse them into a ﬂuid form17,18 (Figure 1d,e). The latter
provides additional beneﬁts, for instance, improved surface-to-
volume ratio,19 availability of an enormous aqueous reservoir
(up to 95−96% of the volume),20,21 rather simple preparation
protocols, low overall viscosity, and rather regular domains
(monodispersed or low polydispersity particles).19 Moreover,
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dispersed lipid particles have great potential for engaging in
targeted and tracked delivery applications.21−29 Upon dis-
persion, the cubic phase is retained within the lipid particles;
hence, the term “cubosomes” (Figure 1e) is used to describe
them.17 As compared to vesicles or liposomes, the bilayer area-
to-particle volume ratio of cubosomes is higher;19 in other
words, cubosomes possess much larger hydrophobic volume
fractions (corresponding values of 0.59 nm3 as compared to
0.18 nm3 for 100 nm sized particles).21 This feature is very
important for enhanced drug carrier capacity, especially for
poorly water-soluble drugs.19 In addition, cubosomes are much
more robust and stable owing to their rather high viscosity that
leads to a resistance to rupture.19
There are several reports demonstrating delivery applications
using the bulk lipid cubic phase30−39 and dispersed nano-
particles like cubosomes,7,19,40−46 but there are hardly any
records where both of these lipid systems have been studied
together under comparable conditions. In this work, we
examined the release properties of the bulk (nondispersed)
lipid cubic phase and its dispersed form, i.e., cubosomes, for a
model drug, aspirin (Figure 1a). Aspirin is an important drug
exhibiting analgesic, antipyretic, and anti-inﬂammatory proper-
ties. Moreover, it was shown to increase the solubility of
cholesterol plaques within the membrane47 and increase its
ﬂuidity. However, aspirin has some predominant side eﬀects
including toxicity to the gastrointestinal tract and rapid
conversion into less desired products.48 Therefore, its
encapsulation into an optimal delivery system would be largely
beneﬁcial.48 We monitored the release of aspirin from the bulk
lipid cubic phase and cubosomes in both water and PBS media
(Figure 1f) using a UV−vis spectroscopic technique.
■ MATERIALS AND METHODS
Materials. A lipid, Dimodan U/J (DU), was generously provided
by Danisco, A/S (Brabrand, Denmark). It is a distilled glyceride
comprising 96% monoglycerides (Figure 1a), and the rest comprises
diglycerides and free fatty acids. Two major monoglyceride
components in DU are linoleate (62%) and oleate (25%). Hence,
the hydrophobic part of DU contains mainly C18 chains (91%). The
following chemicals/items were purchased from Sigma-Aldrich
(Dorset, UK): triblock copolymer Pluronic F127 (PEO99−PPO67−
PEO99) (Figure 1a), used to stabilize lipid particles (cubosomes);
aspirin (chemical name acetylsalicylic acid), which is a salicylate drug
(Figure 1a) used mainly as an analgesic and antipyretic agent;
phosphate buﬀered saline (PBS) tablets; and dialysis membrane sacks
(with an average ﬂat width of 35 mm and a MWCO of 12 000 Da). All
chemicals were used as received without any further puriﬁcation. DU
was stored below 4 °C, whereas the other materials were kept at room
temperature when not in use. Water used during the entire study was
puriﬁed using Barnstead Nanopure system, Thermoscientiﬁc (USA).
Standard Calibration Curves of the Drug in Water and PBS.
Aspirin (50 mg) was dissolved separately in 10 mL of distilled
deionized water (henceforth, “water”) and 10 mL of 0.01 M PBS
buﬀer (one tablet dissolved in 200 mL of deionized water yields 0.01
M phosphate buﬀer at pH ∼ 7.4; henceforth, “PBS”) in 100 mL
volumetric ﬂasks. The mixtures were sonicated for 5 min (Sonics &
Materials Vibra-Cell VCX750, Jencons, UK) to ensure drug
dissolution. Finally, the corresponding volumes were brought up to
the mark with water and PBS to make 0.5 mg/mL stock solutions.
Standard solutions were prepared by appropriate dilutions of the stock
solutions. The absorption spectra of aspirin solutions were determined
in the ultraviolet visible (UV) range of 200−800 nm with the
characteristic λmax at 276 nm (UV-1600PC, VWR, UK). At least 10
dilutions, in the concentration range of 0.1−100 μg/mL, were utilized
to establish standard calibration curves at the λmax (see Supporting
Information Figure S1). All measurements were performed in
triplicates at room temperature (∼25 °C).
Preparation and Loading of the Drug in the Cubic Phase
(Bulk Lipid Phase). The bulk lipid phase was prepared by melting 2 g
of lipid (DU) in a 20 mL glass vial followed by the addition of an equal
amount of water (by weight), yielding a known Pn3m cubic phase49
(Figure 1c). The drug-loaded bulk phase was prepared as follows: A
mixture of the appropriate drug concentration and 1 g of molten DU
was stirred (using a magnetic stirrer bar) for 30 min at 50 °C followed
by the addition of 1 g of water. During the release experiments, a
further 9 g of water was added to 1 g of the cubic phase in order to
maintain concentrations comparable to those of the cubosomes
solution. The hydrated phase was physically mixed with a spatula and
allowed to stand overnight at room temperature.
Preparation and Loading of the Drug in Cubosomes
(Dispersed Lipid Particles). The nanostructured lipid particle
dispersions, i.e., cubosome solutions, were prepared according to a
published method, although slightly diﬀerent parameters and
compositions were used.50 Molten lipid (DU; 500 mg) was added
to a 20 mL glass vial and topped with 9.5 g of F127 stabilizer solution
(already prepared by dissolving 0.5% Pluronic F127 powder in 100 g
of water). The resulting (10 g) mixture was ultrasonicated (Sonics &
Materials Vibra-Cell VCX750, Jencons, UK) for 5 min with a
continuous pulse using 35% of the maximum power. The sample
(milky ﬂuid emulsion, Figure 1e) became hot due to ultrasonication
and was left to cool to room temperature before further usage. Drug-
loaded samples were prepared by stirring the appropriate weight of the
drug in the above cubosome solution for about 20 min at 50 °C.
Drug−Lipid Mixtures and a Release Setup. A drug-loaded bulk
cubic phase mixture (10 g, containing 1 g of lipid cubic phase and 9 g
of water) and 10 g of dispersed cubosomes were loaded with a range of
drug concentrations to obtain ﬁnal samples at 2, 4, 6, and 10 wt %/wt
drug/lipid. The above samples were carefully transferred into dialysis
membrane sacks (which were prepared by heating in pure water for 10
min at 80 °C). Both ends of the membrane sack were tightly tied to
avoid sample leakage. Finally, the membrane sacks were individually
immersed into 200 mL of either water or PBS in 500 mL beakers. A 3
Figure 1. Schematic diagram depicting cubic phases, cubosomes, and
release setup (not to scale). (a) Chemical structures of a lipid
molecule, a surfactant stabilizer, and a drug. Blue and yellow indicates
hydrophilic and hydrophobic parts/regions, respectively. (b) Bicontin-
uous cubic phases of Im3m, Pn3m, and Ia3d types with 6, 4, and 3
corresponding aqueous channels, respectively, as represented by
arrows. (c) Highly viscous cubic phase (Pn3m in the current study)
shown at the bottom of a 20 mL glass bottle. (d) Cubosome (left)
displaying the Im3m phase as an internal self-assembly with surfactant
molecules stabilizing the interface, and a dispersion of such cubosomes
(right). (e) Cubosome dispersion, which is essentially a form of an oil-
in-water emulsion, exhibiting a ﬂuid and milky consistency. (f) Beaker
containing water/PBS with dialysis membrane containing drug-loaded
cubosomes. This represents the typical drug release setup employed in
the current work.
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mL solution from the aforementioned release setup (beaker) was
collected after diﬀerent lengths of time including t = 0 min, and the
UV−vis spectroscopic data was measured at a λmax of 276 nm. After
recording the measurements, the solutions were poured back into their
original reservoir to maintain accumulative release conditions. The
studied drug concentrations were well within sink conditions.51
Entrapment Eﬃciency (%) and Drug Loading (%) in
Cubosomes and Bulk Cubic Phase. Drug (1 g, 2%) loaded
dispersed cubosomes were added to a 1.5 mL Eppendorf tube and
centrifuged at 13 200 rpm for 10 min (Spectrafuge 24D from Jencons
Pls). The ﬂuid phase was transferred into an empty Eppendorf tube
and centrifuged for a further 10 min. The majority of the cubosome
particles were removed by this method; however, the emulsion
retained its opacity. The remaining lipid was separated using an
Amicon Ultra-0.5 centrifugal ﬁlter unit with Ultracel-3 membranes
(NMWL 3 kDa, Millipore, USA) with 20 min of centrifugation at
13 200 rpm. The separated aqueous phase was diluted with water, and
the absorbance at 276 nm was measured using UV−vis spectroscopy.
The entrapment eﬃciency (EE) and drug loading (DL) were
determined using following formulas.52
= − ×
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where CU is the concentration of nonentrapped drug (free unloaded
drug), CT is the concentration of drug added to the cubosome
dispersion, and CL is the total lipid content. The EE and DL values for
the other cubosome dispersions (with 4, 6, and 10% drug) were
determined in the same manner as descried above. Excess water
(aqueous phase) from the drug-loaded bulk cubic phase system was
separated simply by decanting into empty cuvettes followed by
recording the absorbance at 276 nm. The EE and DL values for 2, 4, 6
and 10% drug-loaded bulk cubic phase samples were determined
subsequently using the above formulas (eqs 1 and 2).
Particle Size Analysis of Cubosome Dispersions. The mean
particle size and size distribution of cubosome dispersions were
measured using a Zetasizer Nano ZS instrument (Malvern Instru-
ments, UK) operated at 25 °C.
Detecting the Type of Lipid Nanostructure Using Small
Angle X-ray Scattering. Small angle X-ray scattering (SAXS) was
used to detect the type of lipid nanostructure of the bulk and dispersed
lipid systems (Figure 2). A SAXSpace instrument (Anton Paar, Graz,
Austria) at University of Leeds was employed for this purpose. Details
of the instrument and the measurements were published previously.53
The instrument is based on a Cu anode operating at 40 kV and 50 mA.
Samples were measured using a capillary sample holder controlled at
25 ± 0.1 °C. Typical exposure times of 300 s were suﬃcient to obtain
patterns with well-resolved peaks (Figure 2).
■ RESULTS AND DISCUSSION
Nanostructural Characterization and Drug Loading
Capacity of Bulk Cubic Phase and Cubosomes. The type
of nanostructural self-assembly was determined using SAXS for
drug-loaded and native lipid systems. Bulk DU formed a Pn3m
type bicontinuous cubic phase in excess water,49 which was
retained upon the addition of 10% drug (Figure 2a). In the case
of dispersed lipid systems, the addition of stabilizer molecules
usually caused a phase transition into the Im3m type
bicontinuous cubic phase20,54,55 (Figure 2b).
The ultrasonic dispersion process created discrete lipid
particles with an internal nanostructure of cubic phase. These
cubosomes exhibited a submicrometer size, as veriﬁed by
particle size analysis (for the plot, see Supporting Information
Figure S2). The particle size values for native and drug-loaded
cubosomes are listed in Table 1.
The EE of the bulk lipid cubic phase in excess water and that
of a cubosome dispersion were calculated using eq 1 as shown
in Table 2. Similarly, drug loading in the lipid cubic phase and
in cubosome particles was calculated using eq 2 and is shown in
Table 2. The EE and DL values for the bulk cubic phase were
higher compared to those of the cubosome system. The low DL
values demonstrate that the drug is preferably located in the
aqueous phase rather than in lipid structures. Upon
encapsulation in lipid systems and subsequent dehydration,
the structural features of the drug (aspirin) are generally
protected, as reported in our previous work.56 However, the
lipid systems employed in the current study were always under
excess water conditions, permitting drug encapsulation in both
the lipid and aqueous regions (Table 2).
Figure 2. Detection of the type of lipid self-assembly using SAXS. (a) Observation of the Pn3m cubic phase in pure and drug-loaded (10% drug)
bulk lipid systems. (b) Observation of the Im3m cubic phase in pure and drug-loaded (10% drug) dispersed cubosome systems. Characteristic Bragg
diﬀractions for the Pn3m (√2, √3, √4, √6) cubic phase and the Im3m (√2, √4, √6) cubic phase are shown near the corresponding peaks.
Aqueous channels are indicated by arrows.
Table 1. Particle Size and Polydispersity Indices of Native
and Drug-Loaded Cubosomes Measured by Dynamic Light
Scattering with a Zetasizer Nano ZS
drug in dispersion (wt %/wt of
lipid)
average particle size
(nm)
polydispersity
index
0 194 ± 4 0.210
2 184 ± 3 0.192
4 183 ± 3 0.207
6 182 ± 2 0.205
10 184 ± 1 0.184
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Drug Release from Bulk Cubic Phase. Referring to the
standard calibration curves obtained by dissolving various
concentrations of the drug in water and PBS (Supporting
Information Figure S1), the measured absorbance values at λmax
of 276 nm were translated into percentage (%) release values.
These values were then plotted against time (recorded in
hours) for release from the bulk cubic phase in water (Figure 3)
and PBS (Figure 4).
The curves in Figures 3 and 4 essentially followed typical
drug release kinetics. Their logarithmic plots ﬁtted well (with
correlation coeﬃcient R2 values > 0.96) with the characteristic
Korsmeyer−Peppas equation (eq 3);57,58 for representative ﬁts,
see Supporting Information Figure S3.
=∞M M Kt/t n (3)
where Mt is the amount of drug released at time t, M∞ is the
total amount of drug in the formulation, K is a kinetic constant,
n is the exponent, characteristic of the release mechanism, and t
is the release time in hours.
The release of the drug in water became insigniﬁcant after
about 30 h (Figure 3a), but it was gradual and well-detectable
up to about 96 h using PBS as the release medium (Figure 4a).
The slopes of the ﬁt lines, i.e., release rates in %/h, follow a
linear trend except for the 10% drug sample (Figures 3b and
4b). The corresponding slopes of these lines were comparable:
0.05198% wt%/h for release in water (Figure 3b) and
0.04701% wt%/h for release in PBS (Figure 4b). Both release
rates are dependent on the drug concentration and follow ﬁrst-
order kinetics.
Drug Release from Dispersed Cubosomes. The release
trends from cubosomes (Figure 5) followed similar release
patterns as those from the bulk cubic phase (Figures 3 and 4).
The release in water saturated after about 30 h, whereas it
continued gradually in PBS.
However, the release from cubosomes in water (Figure 5a)
appears to be less dependent on the drug concentration, as
evident from the closely positioned release curves. Never-
theless, the release curves on a log−log scale, both in water and
in PBS, were ﬁtted using the Korsmeyer−Peppas equation (eq
3)57 with typical R2 values > 0.93.
Sustained Drug Release from the Bulk Cubic Phase
Compared to Cubosomes. Comparing the release rates from
cubic phases and cubosomes (Figure 6), it is clear that the
release from cubosomes is faster than the release from bulk
cubic phases. The release of 2% drug from the bulk cubic phase
was found to be sustained 3-fold (0.233%/h) better than the
release from cubosomes (0.658%/h) when measured in water,
whereas it was sustained twice as much from the bulk cubic
phase (0.190%/h) than from cubosomes (0.402%/h) in PBS.
The same trend was also observed for the release rate values of
4% drug in water (0.283%/h for the bulk cubic phase and
0.637%/h for cubosomes) and in PBS (0.282%/h for the bulk
cubic phase and 0.407%/h for cubosomes). The release rates
for 6 and 10% drug from cubosomes were also faster than the
release rates from bulk cubic phases, both in water and PBS.
The goodness of ﬁt of the Korsmeyer−Peppas equation to
almost all curves in both lipid systems helps to understand their
underlying release mechanisms. Analysis of the exponent n (eq
3) suggests that the release mechanism is Fickian diﬀusion
when n is less than or equal to 0.45 (n ≤ 0.45). The release
from the bulk cubic phase, both in water and in PBS, followed
this mechanism. Apparent Fickian diﬀusion is known to
contribute to the sustained release of small molecules from
bulk cubic phases.30,31,35−39 This can be easily attributed to the
highly tortuous porous morphology of cubic phases. In order to
release from the bulk cubic phase, the drug molecule has to
navigate through a lengthy aqueous network assembled by the
long and continuous lipid bilayer architecture. On the contrary,
the release from cubosomes is rapid and less sustained (Figure
6). This is due to their smaller (<200 nm, Table 1)53 particle
size, which is correlated to smaller length scales for drug
transport, and to their surface area being too high, leading to
burst release kinetics.59 The release from cubosomes in water
displayed an n value below 0.45, but for the release in PBS, the
n value was greater than 0.45 (n = 0.63), indicating anomalous
or non-Fickian diﬀusion kinetics.57,58
A few recent reports have demonstrated that the release rates
from lipid systems can be controlled by ﬁne tuning the
nanostructure type and the dimensions of the self-assembled
Table 2. Entrapment Eﬃciency (EE) and Drug Loading
(DL) in the Bulk Lipid Phase and Dispersed Cubosomes
drug
loading
EE bulk cubic phase
in excess water
EE cubosome
dispersion
DL cubic
phase
DL
cubosomes
(wt %/wt
of lipid) (%) (%) (%) (%)
2 84.1 61.9 0.39 0.25
4 98.7 67.6 0.91 0.54
6 98.5 71.3 1.36 0.86
10 96.6 71.6 2.22 1.43
Figure 3. Drug release from the bulk cubic phase in water. (a) Percent (%) drug release calculated from corresponding absorbance values (at λmax of
276 nm) shown against time in hours for 2, 4, 6 and 10% drug. (b) Curves in (a) were ﬁtted with the Korsmeyer−Peppas equation to obtain the
release rates (%/h), which are plotted against the drug-to-lipid ratio.
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phases.30−32,60−62 For instance, if the nanostructure is a
hexagonal phase, the release can be better controlled in
comparison to that of open structured cubic nanostruc-
tures.34,63 Moreover, the release could be promoted via
stimuli-responsive (pH, light, or temperature induced)
triggers.63−65 We have recently demonstrated that it is possible
Figure 4. Drug release from the bulk cubic phase in PBS. (a) Percent (%) drug release calculated from corresponding absorbance values (at λmax of
276 nm) shown against time in hours for 2, 4, 6 and 10% drug. (b) Curves in (a) were ﬁtted with the Korsmeyer−Peppas equation to obtain the
release rates (%/h), which are plotted against the drug-to-lipid ratio.
Figure 5. Drug release from dispersed cubosomes in (a) water and (b) PBS. Percent (%) drug release calculated from corresponding absorbance
values (at λmax of 276 nm) plotted against time in hours for 2, 4, 6 and 10% drug/lipid.
Figure 6. Comparisons of drug release from the bulk cubic phase and cubosomes. Percent (%) release for 2% drug in (a) water and (b) PBS and 4%
drug in (c) water and (d) PBS are shown over time in hours.
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to sustain the release from cubosomes by encapsulating them
into hydrogel ﬁlms.56,66 The release, in this case, is believed to
occur in multiple steps involving hydration of the hydrogel ﬁlm,
swelling and subsequent erosion of the hydrogel, opening of the
aqueous channels of the cubosomes, burst release, and ﬁnally
dissolution of the hydrogel matrix.56
The nanoscale design and dimensions of cubic self-
assemblies further inﬂuence their release kinetics as follows.
The lipid used in this work forms a Pn3m type cubic phase in
pure water49 (Figure 2a). This phase exhibits four aqueous
channels (meeting at a tetrahedral angle), whereas the internal
self-assembly of cubosomes is found to be the Im3m phase
(Figure 2b) consisting of six aqueous channels (meeting at right
angles). Moreover, the aqueous channels of the Im3m phase are
usually larger than those of the Pn3m phase for the same lipid
system; see Table 3. Largely hydrophilic block copolymer
stabilizers, similar to F127 used in this work, are known to alter
the average molecular shape of cubic phase-forming lipids;20,54
the most common result is the formation of the Im3m phase in
the internal cores of dispersed cubosomes.55
The encapsulation of a drug further elevates the diameter of
the aqueous channels by about 22% in the bulk cubic phase and
12% in cubosomes (Table 3). Thus, the number of aqueous
channels and their size are greater in the cubic phase (Im3m) of
cubosomes as compared to those of the bulk cubic phase
(Pn3m), which theoretically contributes to the rather rapid
release from cubosomes.
More Eﬃcient Release in PBS than in Water. Drug
release from all samples, in the bulk cubic phases and
cubosomes, in PBS was far more eﬃcient (more than double
in some cases) than the release in water (Figure 7 and Table 4).
PBS (pH ∼ 7.4) is generally considered to represent
physiological conditions, where drug release kinetics is usually
diﬀerent than under ambient and pure conditions.
The main advantages of employing PBS for release studies
include the retention of a constant pH, prevention of
denaturation and/or conformational changes, resemblance to
body conditions (isotonic), and nontoxicity to cells.68 However,
biological buﬀers and their associated pH aﬀect membrane
properties.68,69 It was envisaged that the buﬀer molecules would
interact with hydrophilic lipid head groups and intercalate
within the headgroup region, facilitating a reduction of the
membrane bending modulus and an increase in the number of
membrane ﬂuctuations.69 The overall eﬀect of these events is
revealed in the form of swelling68 and/or softening of lipid
membranes.69 This could be directly linked to the continued
and eﬃcient release of drug from lipid carriers in PBS in
contrast to the low and halted release in pure water (Figure 7
and Table 4).
The release (%) measured after 24 h for the bulk cubic phase
and cubosomes in both media, i.e., water and PBS, always
decreased with an increase in the drug/lipid ratio (Table 4).
This again conﬁrms that the release rate depends on the drug
concentration, thus following ﬁrst-order release kinetics.
■ CONCLUSIONS AND PERSPECTIVES
In this work, we compared the release properties of two
diﬀerent lipid nanocarrier systems. The bulk lipid cubic phase
and cubosomes were studied under similar drug-to-lipid ratios
Table 3. Nanoscale Dimensions of Lipid Cubic Phases Formed in the Bulk System and Dispersed Systems before and after Drug
Loadinga
physical form of lipid
system
concentration of drug
wt %/lipid wt
type of self-assembled cubic
phase
no. of aqueous
channels
lattice parameter
(a; Å)
diameter of aqueous channel
(dw; Å)
bulk cubic phase 0 Pn3m 4 89.5 37.9
bulk cubic phase 10 Pn3m 4 103.2 48.7
dispersed cubosomes 0 Im3m 6 135.6 50.9
dispersed cubosomes 10 Im3m 6 146.7 57.8
aLattice parameters and diameters of aqueous channels were calculated according to the formulae listed in ref 67.
Figure 7. Drug release in PBS compared to water. Percent (%) drug release in water (solid squares) and in PBS (solid circles) for 2% drug/lipid is
shown for the (a) bulk cubic phase and (b) cubosome system. Note that the representative data plots for 2% drug/lipid samples are shown here; for
remaining data plots (4, 6, and 10% drug/lipid), see Supporting Information Figure S4.
Table 4. Percent Release at 24 h from Both Lipid Systems in
Water and PBS
drug
(wt %/wt of
lipid)
bulk cubic
phase in water
(%)
bulk cubic
phase in PBS
(%)
cubosomes
in water (%)
cubosomes
in PBS (%)
2 33.65 45.12 30.93 56.53
4 24.62 41.11 29.47 44.39
6 22.91 34.39 29.16 41.67
10 20.09 31.05 18.23 38.96
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and volumes of release media. Drug release in both lipid
systems followed a mechanism described by the Korsmeyer−
Peppas equation, revealing Fickian diﬀusion through the porous
matrix.57,58 However, the diﬀusion from cubosomes in PBS was
anomalous, involving either or a combination of non-Fickian
diﬀusion and erosion.57,58 The latter may correspond to the
interaction of PBS buﬀer molecules with lipid bilayer
structures68,69 that are enclosed by small cubosome particles.
This can be veriﬁed by the eﬃcient and rapid release in PBS
compared to the almost stopped release in water (Figure 7).
The release from bulk lipid systems was sustained with
respect to the dispersed colloidal cubosomes for apparent
reasons. Although both lipid systems exhibit self-assembled
cubic nanostructures with highly tortuous porous networks, the
eﬀective length scales experienced by the drug molecules diﬀer
enormously. Cubosome particles are small in size with a rather
high interfacial area, leading to a burst release, whereas the
longer length scales of the bulk cubic phase enable prolonged
drug release. Moreover, the wider and higher number of
aqueous channels of the Im3m cubic phase contribute to the
enhanced release from cubosomes. At this stage, we cannot
comment on the role of the overall high viscosity of bulk cubic
phases in the release kinetics, and we leave this for further in-
depth studies. This study sheds light on an important aspect of
comparing two emerging drug delivery systems based on the
nanoscale self-assembly of lipid molecules in aqueous media.
The results obtained are potentially useful for predicting the
design of and optimizing these nanocarrier systems.
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